Skip to main content

Advertisement

Table 1 Patient characteristics

From: Rheumatoid arthritis–associated autoantibodies in non–rheumatoid arthritis patients with mucosal inflammation: a case–control study

Patient group Rheumatoid arthritis Periodontitis Bronchiectasis Cystic fibrosis Healthy controls p value (vs. HC)
Subjects (n) 86 114 80 41 36  
Age, yr, median (IQR) 57 (48–64) 50 (45–57) 65 (56–71) 28 (21–36) 26 (24–46) ***RA, PD and BR
Female (%) 56 59 63 49 60 n.s.
Current smoker (%) 60 42 2.5 0 14 **PD, *for BR and CF
Ever smoker (%) 17 36 44 0 8.3 **PD, ***BR
Never smoker (%) 22 22 54 100 78 ***PD, *BR, **CF
PISA (cm2), median (IQR) n.a. 14 (9.0–19) n.a. n.a. n.a.  
%FEV1, median (IQR) n.a. n.a. 81 (60–97) 54 (36–80) n.a.  
Exacerbations (n), median (IQR) n.a. n.a. 4 (3–6) 2 (1–3) n.a.  
DAS28, median (IQR) 2.2 (1.7–2.8) n.a. n.a. n.a. n.a.  
CRP (mg/L), median (IQR) 1.9 (1.0–6.0) 1.0 (0.6–2.4) 5 (2.0–13) 6.0 (4.0–14) 0.4 (0.3–1.5) ***RA, BR and CF
No periodontitis (%) 31 0 n.a. n.a. 100  
Moderate periodontitis (%) 41 0 n.a. n.a. 0  
Severe periodontitis (%) 28 100 n.a. n.a. 0  
Porphyromonas gingivalis-positive (%) 14 43 n.a. n.a. 0  
MTX (%) 71      
aTNFα (%) 10      
SASP (%) 3.5      
MTX + aTNFα (%) 3.5      
MTX + SASP (%) 4.7      
Other (%) 3.5      
None (%) 3.5      
  1. aTNFα anti-TNFα inhibitors, CRP C-reactive protein, DAS28 Disease Activity Score 28 tender and swollen joint count, Exacerbations based on the number of antibiotic courses 12 months before inclusion, %FEV 1 percentage predicted forced expiratory volume, MTX methotrexate, n.a. not assessed, n.s. not significant, PISA periodontal inflamed surface area, SASP sulfasalazine
  2. *p < 0.05, **p < 0.01, ***p < 0.0001 (Kruskal–Wallis one-way analysis of variance with Dunn’s multiple-comparisons post-test or Fisher’s exact test with two-tailed p value)